Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer
Original Article on Endometrial Cancer

Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer

Federico Ferrari1, Sara Forte2, Giulia Arrigoni2, Laura Ardighieri3, Maria Consuelo Coppola2, Federica Salinaro1, Fabio Barra4,5, Enrico Sartori2, Franco Odicino2

1Department of Obstetrics and Gynecology, Spedali Civili of Brescia, Brescia, Italy; 2Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy; 3Department of Pathology, Spedali Civili of Brescia, Brescia, Italy; 4Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 5Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Contributions: (I) Conception and design: F Ferrari; (II) Provision of study materials or patients: S Forte, F Salinaro; (IV) Collection and assembly of data: G Arrigoni, L Ardighieri, MC Coppola; (V) Data analysis and interpretation: F Salinaro, F Barra, E Sartori; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Fabio Barra, MD. Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genova, Italy. Email:

Background: Histotype and tumor grading of endometrial cancer are the most important factors that have to be assessed by preoperative endometrial sampling, and their concordance with the final surgical and definitive histological findings is of paramount importance. We aim to compare histotype and tumor grading concordance of various endometrial sampling techniques (ESTs) and to investigate the role of endometrial volume biopsy.

Methods: We performed a retrospective analysis of patients with apparent early stage endometrial cancer collecting demographic, clinical data, type of EST, pathological characteristics of endometrial biopsies and final specimens. We classified ESTs as dilation and curettage (D&C), diagnostic hysteroscopy with D&C, outpatient hysteroscopy and operative hysteroscopy with or without D&C. Diagnostic and operative hysteroscopy were performed with Bettocchi’s 5 mm hysteroscope. We evaluated concordance for histotype, and tumor grading, and we performed subgroup analysis based on the technique and final tumor grading. Concordance was classified from good, moderate, sufficient, fair, poor and none using Cohen k-statistic. Finally, we investigated the existence of independent risk factors for discordant tumor grading using multivariate binary logistic regression.

Results: We collected 148 patients and of these 131 (88.5%) were diagnosed with endometrioid histotype and 65 (44%), 46 (31%) and 37 (25%) respectively with well, moderate and poor differentiated tumors. Atypical hyperplasia (AH) was detected preoperatively in 28 patients (19%). Histotype concordance was fair (k=0.35) and tumor grading concordance was moderate (k=0.45); particularly, concordance was fair in well-differentiated cases (k=0.38); concordance was moderate in moderate- and poor-differentiated cases (k=0.52) and good (k=0.71). Operative hysteroscopy showed moderate concordance for histotype (k=0.41), while grading concordance was fair for G1 (k=0.41), moderate for G2 (k=0.58) and good for G3 (k=0.72), regardless the use of D&C. Preoperative volume biopsy did not impact the concordance of tumor grading, while the adoption of operative hysteroscopy (with or without D&C) decreased the risk of grading discordance in G3 tumors (HR 0.17; 95% CI: 0.03–0.94; P=0.04). Conversely, time elapsed from diagnosis to treatment in well-differentiated tumors increased the risk of discordant results (HR 1.06; 95% CI: 1.02–1.52; P=0.04).

Conclusions: Operative hysteroscopy demonstrated the best tumor grading concordance, especially in poor-differentiated tumors. The volume of biopsy did not affect the tumor grading concordance.

Keywords: Endometrial biopsy; endometrial cancer; grading; hysteroscopy

Submitted May 13, 2020. Accepted for publication Jul 06, 2020.

doi: 10.21037/tcr-20-2074


Endometrial cancer is the most common gynecological malignancy in developed countries with a cumulative risk, up to seventy-five years old, equal to 1.6% (1). So far, most of these cancers are diagnosed at an early stage, with low risk of recurrence, and do not require adjuvant therapy (2). However, approximately 20% of the patients have a worse outcome in terms of recurrence and survival (3), depending on prognostic factors such as myometrial infiltration (MI), lymph nodal status, histotype and tumor grading (4). Endometrial sampling is a fundamental step in preoperative workup (5,6) and it aims to predict the two latter aforementioned factors (7), to tailor the surgical approach (8,9) and lymph nodal staging (10). In fact, the risk of under- or overestimating an endometrial malignancy can lead to a wrong therapeutic approach (11).

Unfortunately, preoperative endometrial sampling was found to be only a modest predictor of the final diagnosis (12,13). In fact, several studies compared various endometrial sampling techniques (ESTs) evaluating their concordance with the final histology (14,15) and, currently, there is not clear evidence on which EST has the better diagnostic accuracy. Moreover, many limiting factors can interfere with the choice of the EST, such as pain uterine bleeding, cervical stenosis and contraindication to general anesthesia (16-19). Occasionally, the amount of tissue obtained is so minimal that diagnosis cannot be reached and furthermore, to date, specific quantitative criteria for an adequate endometrial sample have not been established yet as a standard of care (20,21).

The aim of our study is to compare the histotype and tumor grading concordance of preoperative endometrial sampling with the final specimen of endometrial cancer across different ESTs and to investigate the impact of endometrial volume biopsy in tumor grading concordance. We present the following article in accordance with the STROBE reporting checklist.


We performed a single center mono-institutional retrospective study, using a surgical electronic database, of consecutive patients who underwent preoperative endometrial sampling and subsequent surgical treatment for endometrial cancer, from January 2014 to December 2018 at the Department of Obstetrics and Gynecology of ASST Spedali Civili of Brescia, a tertiary northeastern university hospital in Italy. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Institutional Review Board of the hospital approved this study (Protocol number 3398) and patients signed an informed consent.

Indeed, we excluded patients underwent preoperative endometrial biopsy at external institution and subsequently referred to our hospital for staging and treatment.

We collected demographic data such as age at surgery, parity, BMI, presence of abnormal uterine bleeding (AUB) and the type of endometrial sampling. At our institution, we adopted a specific EST based on detailed criteria, according to the clinical presentation. In fact, we classified ESTs as follows: (I) dilatation and curettage (D&C), performed in case of active uterine bleeding that usually prevents the view of the cavity; (II) outpatient biopsy with 5 mm Bettocchi’s hysteroscope, using either micro scissors and/or forceps (22), performed in case of anesthesiological contraindication; (III) diagnostic hysteroscopy with 5 mm Bettocchi’s hysteroscope followed by D&C, performed in case no suspicious endometrial area was found for selective biopsy; (IV) operative hysteroscopy with cervical dilatation, using saline solution for uterine distention and resectoscope, performed in all the remaining cases and, finally; (V) operative hysteroscopy with cervical dilatation, performed as previously mentioned and followed by D&C, in case of subjective impression of scanty material obtained after resectoscopic biopsy. All procedures, except outpatient hysteroscopy, were performed under general anesthesia. Final surgical treatment included peritoneal cytology, hysterectomy and bilateral salpingo-oophorectomy with or without nodal staging, namely with sentinel lymph node biopsy or pelvic and/or aortic lymphadenectomy based on preoperative imaging and biopsy histology and grading. Endometrial tissue obtained by different ESTs was sampled and entirely submitted for histological examination; the sampling method included a description of the macroscopic features of the tissue (consistency, color, presence of blood cot and mucus) and measurement of its amount. Of note, a standardized and reproducible method to assess tissue amount was performed: tissue fragments obtained by biopsy were measured as a three-dimension (height, width and depth in millimeters) tissue aggregate; subsequently, a total tissue volume was calculated and expressed as cubic centimeters (cc). A detailed clinical history including patients’ age, symptoms, menopausal status, date of onset of the last menstrual cycle, length of menstrual cycle, and hormonal therapy was provided for pathological evaluation. Dedicated gynecological pathologist analyzed preoperative endometrial tissue and final uterine surgical specimen and classified histological findings according to the criteria of WHO Classification of Female Genital Tract Tumors (23-25). Of note, at our Hospital Institution, the same pathologist analyzed both the preoperative biopsy and the final specimen from hysterectomy of every single case, reducing the bias of interobserver agreement in assessing tumor grade/histology. The minimum criteria adequacy for the endometrial biopsy was the presence of 10 endometrial strips for postmenopausal women (according to Sakhadari’s study are sufficient to exclude a malignant process, with a negative predictive value close to 100%) and the presence of at least one intact endometrial tissue fragment containing both glands and stroma for premenopausal ones (26).

We performed standard descriptive statistic calculating sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy for histotype and tumor grading diagnosis. We evaluated the concordance for histotype and tumor grading between endometrial sampling and final histology using Cohen k-statistic. Subsequently, we performed subgroup analysis clustered for the aforementioned ESTs and for each final tumor grade, namely well (G1), moderate (G2) and poor (G3) differentiated. The conventional Choen k-value scheme was applied for agreement as follows: <0 for “none”, 0–0.19 for “poor”, 0.2–0.39 for “fair”, 0.4–0.59 for “moderate”, 0.6–0.79 for “good” and 0.8–1 for “excellent” (27). Finally, we performed a multivariate binary logistic regression to investigate the impact of various factors on tumor grading concordance between endometrial biopsy and final specimen. We included as risk factors: age, BMI, menopausal status, ultrasound endometrial thickness in millimeters, suspect of MI at ultrasound greater than 50%, the type of EST, the volume of the endometrial biopsy in cubic centimeters and time elapsed from diagnosis to treatment in days. We used IBM SPSS Statistics for Windows, Version 23.


We identified 148 patients and clinical characteristics are shown in Table 1; of note, 135 (91.2%) patients were in menopause and 121 (81.8%) presented with AUB as initial symptom. Most of the patients underwent operative hysteroscopy (n=58; 39.2%) and office hysteroscopy (n=40; 27%), while diagnostic hysteroscopy with D&C and operative hysteroscopy with D&C were performed respectively in 11.4% (n=17) and 13.5% (n=20) of cases (Table 1). We finally diagnosed 131 (88.5%) endometrioid and 17 (11.5%) non-endometrioid carcinomas; the accuracy for endometrioid histotype is 77% (sensitivity 78%; specificity 63%; PPV 94%; NPV 30%). Subgroup analysis for each tumor grade (G1, G2 and G3) revealed a low sensitivity for well-differentiated tumor, with a mean accuracy of 80% (Table 2), regardless of the type of EST.

Table 1

Clinical characteristics of the patients

Variables n=148
   Mean (range) 64.6 [21–95]
   Median (IQR) 65 [57–73]
   Mean (range) 27.9 (13.9–49)
   Median (IQR) 27.2 (23–31.7)
Menopause 135 (91.2%)
AUB 121 (81.8%)
DM 26 (17.6%)
Tamoxifen use 5 (3.3%)
Abnormal ultrasound findings 109 (74%)
   Endometrial thickness ≥5 mm 84 (57%)
   Suspicious lesion or polyp 25 (17%)
   Myometrial invasion ≥50% 79 (53.4%)
Final histotype
   Endometrioid 131 (88.5%)
   Non endometrioid 17 (11.5%)
    Serous 8 (5.4%)
    Carcinosarcoma 3 (2%)
    Undifferentiated 2 (1.4%)
    Other 3 (2%)
    Clear cell 1 (0.7%)
Endometrial sampling techniques
   D&C 13 (8.8%)
   Diagnostic hysteroscopy with D&C 17 (11.4%)
   Office hysteroscopy 40 (27%)
   Operative hysteroscopy 58 (39.2%)
   Operative hysteroscopy with D&C 20 (13.5%)
Endometrial biopsy volume (cc)
   Mean (range) 4.5 (0.5–25)
   Median (IQR) 3.5 (1.5–6)
Time from diagnosis to treatment (days)
   Mean (range) 45 [4–232]
   Median (IQR) 39 [31–57]

Data is presented as n (%) where not specified. IQR, inter quartile range; BMI, body mass index; AUB, abnormal uterine bleeding; DM, diabetes mellitus; D&C, dilation and curettage; cc, cubic centimeters.

Table 2

Diagnostic performance for final tumor grading

Grade Sensitivity (%) Specificity (%) NPV (%) PPV (%) Accuracy (%)
G1 51 89 78 70 71
G2 65 85 67 84 79
G3 76 93 80 92 89
Mean 64 89 75 82 80

G1, grade 1; G2, grade 2; G3, grade 3; NPV, negative predictive value; PPV, positive predictive value.

Overall concordance for histotype, regardless EST, was fair (k=0.36; SE 0.08; 95% CI: 0.08–0.41; P<0.00), given 27 patients (17.6%) with a preoperative finding of atypical hyperplasia (AH) that finally revealed an endometrioid carcinoma. On the contrary, adoption of operative hysteroscopy with or without D&C showed moderate histotype concordance (k=0.41; SE 0.096; 95% CI: 0.17–0.55; P<0.00).

Overall concordance for tumor grading (Table 3) was moderate (k=0.46; SE 0.05; 95% CI: 0.36–0.56; P<0.00). Subgroup analysis of grading concordance, regardless EST adopted, showed good concordance for G3 (k=0.71; SE 0.07; 95% CI: 0.57–0.84; P<0.00), moderate for G2 (k=0.52; SE 0.07; 95% CI: 0.38–0.67; P<0.00) and only fair for G1 (k=0.39; SE 0.07; 95% CI: 0.24–0.53; P<0.00). Subsequent analysis, clustered for ESTs, demonstrated a moderate tumor grading concordance for operative hysteroscopy (k=0.54; SE 0.08; 95% CI: 0.37–0.70; P<0.00) and for operative hysteroscopy with D&C (k=0.53; SE 0.14; 95% CI: 0.26–0.79; P<0.00), without any statistical difference between the groups (P=0.87). Notably, patients underwent endometrial biopsy with operative hysteroscopy (both with and without D&C) showed a moderate concordance for G1 (k=0.418; SE 0.082; 95% CI: 0.26–0.57; P<0.00) and good for G2 (k=0.62; SE 0.081; 95% CI: 0.41–0.73; P<0.00) and for G3 (k=0.721; SE 0.075; 95% CI: 0.57–0.86; P<0.00). Multivariate logistic regression analysis (Table 4) identified two factors influencing tumor grading concordance: time from diagnosis to treatment in G1 tumors (HR 1.06; 95% CI: 1.02–1.52; P=0.04) can slightly increase the risk of discordance, while the use of operative hysteroscopy in G3 tumors (HR 0.17; 95% CI: 0.03–0.94; P=0.04) instead reduces the chance of discordance. Interestingly, preoperative biopsy volume did not affect the chance to increase concordance for tumor grading (Table 4).

Table 3

Concordant and discordant cases of tumor grading

Final tumor grading Pre-operative tumor grading (%) Total k P value
AH G1 G2 G3
G1 27 (41.5) 31 (47.5) 7 (11.0) 65 (44.0) 0.39 <0.00
G2 1 (2.2) 8 (17.4) 30 (65.2) 7 (15.2) 46 (31.0) 0.52 <0.00
G3 1 (2.7) 8 (21.6) 28 (75.7) 37 (25.0) 0.71 <0.00
Total 28 (19.0) 40 (27.0) 45 (30.4) 35 (23.6) 148 (100.0) 0.46 <0.00

AH, atypical hyperplasia; G1, grade 1; G2, grade 2; G3, grade 3; k, Coehn’s Kappa.

Table 4

Multivariate logistic regression analysis of factors influencing final tumor grading concordance

Variables Final tumor grading
G1 G2 G3
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Age 1.05 0.98–1.11 0.132 1.01 0.96–1.07 0.693 1.03 0.96–1.10 0.46
Menopause 0.172 0.03–1.02 0.06 0.43 0.08–2.44 0.341 0.62 0.08–4.57 0.64
BMI 0.99 0.91–1.08 0.83 0.97 0.89–1.06 0.52 0.95 0.85–1.07 0.46
Ultrasound endometrial thickness (mm) 0.95 0.90–1.02 0.11 0.98 0.93–1.04 0.48 1.00 0.94–1.07 0.89
Ultrasound MI ≥50% 0.82 0.27–2.56 0.74 1.5 0.45–4.96 0.50 0.53 0.12–2.40 0.41
Operative hysteroscopy 0.78 0.28–2.28 0.65 0.42 0.14–1.25 0.12 0.17 0.03–0.94 0.04
Preoperative biopsy volume (cc) 0.98 0.85–1.14 0.83 1.00 0.89–1.13 0.95 1.02 0.87–1.18 0.85
Time to treatment (days) 1.06 1.02–1.52 0.04 0.97 0.95–1.02 0.07 0.98 0.95–1.02 0.24

In italic the statistically significant results. G1, grade 1; G2, grade 2; G3, grade 3; HR, hazard ratio; CI, confidence interval; BMI, body mass index; mm, millimeters; MI, myometrial invasion; cc, cubic centimeters.


Operative hysteroscopy with resectoscopic biopsy is the most reliable technique for endometrial sampling in case of suspected endometrial cancer, owing to a moderate concordance for both histotype and tumor grading. Endometrioid well-differentiated carcinoma suffer misdiagnosis, mainly due to AH at preoperative endometrial biopsy and to carcinoma progression during the time from diagnosis to treatment.

In a meta-analysis on 1,106 patients, hysteroscopic resection presented the lower recurrence rate of unexpected endometrial cancer after hysterectomy for atypical endometrial hyperplasia (5.8%) compared with D&C and hysteroscopically guided biopsy, respectively 32.7% and 45.3% (28). However, a retrospective Polish study showed a higher level of concordance with D&C, especially for endometrioid carcinomas and a moderate strength of association between initial and final diagnosis for all histotype of endometrial cancer. Interestingly, the lowest concordance in tumor grading definition between D&C and final histology was detected for well-differentiated cancers, while in moderate- and poor-differentiated tumors, concordance levels were more elevated, 75.8% and 73.3% respectively (29). On the contrary, in 2017, the research group of the National Cancer Institute of Milan published a retrospective analysis of patients underwent preoperative hysteroscopy reporting an overall level of agreement between preoperative and postoperative tumor grading that was moderate and good respectively for G2 and G3 tumors (k=0.531; 95% CI: 0.286–0.777; P<0.001 and k=0.774; 94% CI: 0.534–1; P<0.001 respectively) while it was moderate in well differentiated tumors (k=0.679; 95% CI: 0.432–0.926; P<0.001); of note, they further reported an overall accuracy in detecting endometrial cancer of 80.2% (30). Similarly, in a more recent systematic review and meta-analysis on 12,459 patients, hysteroscopic endometrial biopsy demonstrated a greater level of accuracy in well and poor differentiated tumors but with a lower agreement rate for G2 tumors (31). Lago et al. confirmed the limitations in the assessment of tumor grading for various preoperative biopsy procedures (D&C, Pipelle and hysteroscopy procedures) and particularly in G1, G2 and big tumors, while G3 tumors showed better correlation with final histology. Hysteroscopy presented the highest tumor grading agreement, but no difference between the three analyzed methods was found (hysteroscopy, D&C and Pipelle with respectively k=0.55, k=0.39 and k=0.43). Interestingly, the authors hypothesize that the low volume of tissue available at biopsy had an influence in the tumor grade discrepancies in the final pathological assessment (15).

In our study, we included most of the known and widespread adopted ESTs, and we specifically differentiated among the various hysteroscopic procedures with subgroup analysis. Operative hysteroscopy with resectoscopic biopsy resulted to be the most reliable procedure that can predict histotype and tumor grading, showing for both a moderate concordance with the final diagnosis (respectively with k=0.41 and k=0.54). The addition of subsequent D&C after operative hysteroscopy, generally aimed to increase the sample volume and hence improve accuracy, did not improve the strength of concordance for tumor grading (k=0.53). These data seem to suggest that the visual examination of suspicious endometrial area under hysteroscopic view lead to a higher diagnostic accuracy, especially if biopsy is performed with a subsequent resectoscopic biopsy. In fact, outpatient hysteroscopy as well as diagnostic hysteroscopy and D&C lead to lower levels of concordance for tumor grading (respectively k=0.31 and k=0.33). Nonetheless, we failed to identify a role in the volume biopsy as a predictor of tumor grading concordance, supporting hence the impact of direct visualization of a suspicious endometrial area. Finally, a greater time elapsed from diagnosis to treatment resulted to be a risk for carcinoma progression in well-differentiated tumor, even though this result can be due to the diagnosis of preoperative AH.

In accordance with the results from Lago (15) and the National Cancer Institute of Milan research group (30), the best diagnostic accuracy in our series was found for poor differentiated tumors, while our concordance was moderate for G2 tumors and only fair in G1 tumors. These results were confirmed including all preoperative ESTs, while in a separated analysis, we noticed a moderate concordance also for well-differentiated tumors in case of operative hysteroscopy (with or without D&C). The analysis of literature and of our series show that the major discrepancies in the definition of tumor grade were seen in well- and moderate-differentiated tumors that fall within the low and intermediate risk subgroups of endometrial cancer (7) for which lymph nodal staging is debated. In the next future to overcome this issue, molecular classification (32) and new methods of genetic analysis (33) will be hopefully able to predict genomic sub types through a preoperative biopsy that would more accurately guide the definition of surgical treatment. The recent PROMISE characterization is able to classify endometrial cancer in four prognostic groups based on molecular findings (34), even though there is a not negligible quote of unclassifiable cases (35). Ideally, a preoperative framing of these molecular groups can be of extreme usefulness to tailor the lymph nodal staging to avoid late complications such as the legs’ lymphedema or avoid radiotherapy with its related side effects. So far, this classification can be used also in the post-operative setting to establish the need for adjuvant treatment in those cases with apparent low risk endometrial cancer. To ensure the success of the genomic testing it’s recommendable to perform endometrial sampling with the most reliable technique, such as operative hysteroscopy with resectoscopic biopsy to obtain the most representative sample of tissue for diagnosis and genomic testing (36). Nonetheless, future endometrial biopsy techniques with miniaturization and consensual optimization of the biopsy instruments should be implemented (37), given the importance of the direct view of the target area for biopsy (38). Further studies on the prognostic definition of genomic sub types, both for endometrioid and non-endometrioid carcinomas found at preoperative biopsy, are required and given the small numbers of non-endometrioid carcinomas, multicentric studies are warranted with standardized methods of endometrial sampling and central pathological review.

Actually, the adequacy of the EST is a fundamental step for the tailoring of surgical extension, in particularly regarding the type of lymph nodal staging (39). In fact, while for ovarian cancer the open debate regards the different therapeutic surgical strategies to predict and to achieve a complete resection (40-44), instead, for endometrial, and similarly for vulvar (45) and cervical cancer (46), the current research topic is the validity of sentinel lymph node technique (47-49).

Our study has strengths and limitations. Among strengths, we included only consecutive patients with apparent early stage endometrial cancer diagnosed and treated in a single institution to decrease inter-observer agreement, and we conducted subgroup analysis of the different ESTs, with particular emphasis regarding the different type of hysteroscopic procedures and detailed framework for the selection of the EST. Among limitations, our study is a retrospective analysis, with a relatively small sample size, and it may not be exempt by potential selection bias.


According to our findings, we recommend a resectoscopic biopsy during hysteroscopy to minimize misdiagnosis of endometrial cancer and erroneous tumor grading classification. In case of suspect of endometrial cancer, surgeons should be aware that using other methods of endometrial sampling, in view of limiting factors for operative hysteroscopy, increases the risk of discordant tumor grading. Nonetheless, the volume of the endometrial biopsy does not affect the accuracy of tumor grading concordance. Lastly, a promptly treatment should be delivered to decrease the chance of cancer progression in well-differentiated tumors.


To medical and nursery staff of Department of Obstetrics and Gynecology of Spedali Civili Brescia (Italy).

Funding: This paper was funded by Lega Italiana per la Lotta contro i Tumori - LILT - Bando 5×1000 anno 2019.


Provenance and Peer Review: This article was commissioned by the Guest Editor (Antonio Simone Laganà) for the series “Endometrial Cancer” published in Translational Cancer Research. The article has undergone external peer review.

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at

Data Sharing Statement: Available at

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at The series “Endometrial Cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study has been approved by the local ethic committee (approval number 3398) and a written informed consent was obtained from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet 2018;143:37-50. [Crossref] [PubMed]
  2. Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet 2019;299:299-315. [Crossref] [PubMed]
  3. Franchi M, Garzon S, Zorzato PC, et al. PET-CT scan in the preoperative workup of early stage intermediate- and high-risk endometrial cancer. Minim Invasive Ther Allied Technol 2020;29:232-9. [Crossref] [PubMed]
  4. Casarin J, Bogani G, Serati M, et al. Presence of glandular cells at the preoperative cervical cytology and local recurrence in endometrial cancer. Int J Gynecol Pathol 2020;39:522-8. [Crossref] [PubMed]
  5. Barra F, Ferrero S. Transvaginal ultrasound assessment. In: Ferrero S. editor. Endometrial Cancer: Risk Factors, Management and Prognosis. Nova Publishers, 2018.
  6. Chiofalo B, Mazzon I, Di Angelo Antonio S, et al. Hysteroscopic evaluation of endometrial changes in breast cancer women with or without hormone therapies: results from a large multicenter cohort study. J Minim Invasive Gynecol 2020;27:832-9. [Crossref] [PubMed]
  7. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Radiother Oncol 2015;117:559-81. [Crossref] [PubMed]
  8. Vitale SG, Rossetti D, Tropea A, et al. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg 2017;69:29-34. [Crossref] [PubMed]
  9. Majd HS, Ferrari F, Gubbala K, et al. Latest developments and techniques in gynaecological oncology surgery. Curr Opin Obstet Gynecol 2015;27:291-6. [Crossref] [PubMed]
  10. Centurioni MG, Barra F, Gustavino C, et al. Sentinel-node mapping by intraoperative near-infrared fluorescence in the robotic surgical treatment of endometrial cancer. J Gynecol Surg 2019;35:205-7. [Crossref]
  11. Cignini P, Vitale SG, Laganà AS, et al. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg 2017;69:75-82. [Crossref] [PubMed]
  12. Batista TP, Cavalcanti CLC, Tejo AAG, et al. Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma. Eur J Surg Oncol 2016;42:1367-71. [Crossref] [PubMed]
  13. van Hanegem N, Prins MMC, Bongers MY, et al. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2016;197:147-55. [Crossref] [PubMed]
  14. Gkrozou F, Dimakopoulos G, Vrekoussis T, et al. Hysteroscopy in women with abnormal uterine bleeding: a meta-analysis on four major endometrial pathologies. Arch Gynecol Obstet 2015;291:1347-54. [Crossref] [PubMed]
  15. Lago V, Martín B, Ballesteros E, et al. Tumor grade correlation between preoperative biopsy and final surgical specimen in endometrial cancer: the use of different diagnostic methods and analysis of associated factors. Int J Gynecol Cancer 2018;28:1258-63. [Crossref] [PubMed]
  16. Mazzon I, Favilli A, Grasso M, et al. Pain in diagnostic hysteroscopy: A multivariate analysis after a randomized, controlled trial. Fertil Steril 2014;102:1398-403. [Crossref] [PubMed]
  17. Mazzon I, Favilli A, Horvath S, et al. Pain during diagnostic hysteroscopy: What is the role of the cervical canal? A pilot study. Eur J Obstet Gynecol Reprod Biol 2014;183:169-73. [Crossref] [PubMed]
  18. Favilli A, Mazzon I, Gerli S. Pain in office hysteroscopy: it is not just a matter of size. Comment on: “Paulo AA, Solheiro MH, Paulo CO. Is pain better tolerated with mini-hysteroscopy than with conventional device? A systematic review and meta-analysis: hysteroscopy scope size and p. Arch Gynecol Obstet 2016;293:687-8. [Crossref] [PubMed]
  19. Aue-Aungkul A, Kleebkaow P, Kietpeerakool C. Incidence and risk factors for insufficient endometrial tissue from endometrial sampling. Int J Womens Health 2018;10:453-7. [Crossref] [PubMed]
  20. Mazzon I, Grasso M, Favilli A, et al. Hysteroscopic Aspects of Endometrial Ossification. J Minim Invasive Gynecol 2013;20:408-9. [Crossref] [PubMed]
  21. Kandil D, Yang X, Stockl T, et al. Clinical outcomes of patients with insufficient sample from endometrial biopsy or curettage. Int J Gynecol Pathol 2014;33:500-6. [Crossref] [PubMed]
  22. Romani F, Guido M, Morciano A, et al. The use of different size-hysteroscope in office hysteroscopy: our experience. Arch Gynecol Obstet 2013;288:1355-9. [Crossref] [PubMed]
  23. Hanby AM, Walker C. Tavassoli FA, Devilee P: Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series - volume IV. Lyon, France: IARC Press, 2003.
  24. Williams SA, Ehlers RA, Hunt KK, et al. Metastases to the breast from nonbreast solid neoplasms: Presentation and determinants of survival. Cancer 2007;110:731-7. [Crossref] [PubMed]
  25. Kurman RJ, Carcangiu ML, Herrington CS. WHO Classification of Tumours of Female Reproductive Organs 2014.
  26. Sakhdari A, Moghaddam PA, Liu Y. Endometrial samples from postmenopausal women: A proposal for adequacy criteria. Int J Gynecol Pathol 2016;35:525-30. [Crossref] [PubMed]
  27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. [Crossref] [PubMed]
  28. Bourdel N, Chauvet P, Tognazza E, et al. Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 2016;23:692-701. [Crossref] [PubMed]
  29. Kisielewski F, Gajewska ME, Marczewska MJ, et al. Comparison of endometrial biopsy and postoperative hysterectomy specimen findings in patients with atypical endometrial hyperplasia and endometrial cancer. Ginekol Pol 2016;87:488-92. [Crossref] [PubMed]
  30. Martinelli F, Ditto A, Bogani G, et al. Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies. J Cancer Res Clin Oncol 2017;143:1275-9. [Crossref] [PubMed]
  31. Visser NCM, Reijnen C, Massuger LFAG, et al. Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review and Meta-analysis. Obstet Gynecol 2017;130:803-13. [Crossref] [PubMed]
  32. Piulats JM, Guerra E, Gil-Martín M, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 2017;145:200-7. [Crossref] [PubMed]
  33. Muinelo-Romay L, Casas-Arozamena C, Abal M. Liquid biopsy in endometrial cancer: New opportunities for personalized oncology. Int J Mol Sci 2018;19:2311. [Crossref] [PubMed]
  34. Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802-13. [Crossref] [PubMed]
  35. Maxwell GL, Mutch DG. The promise of molecular staging for the future. Cancer 2017;123:728-30. [Crossref] [PubMed]
  36. Bellone S, Bignotti E, Lonardi S, et al. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol 2017;144:146-52. [Crossref] [PubMed]
  37. Vitale SG. The Biopsy Snake Grasper Sec. VITALE: A New Tool for Office Hysteroscopy. J Minim Invasive Gynecol 2020;271414-6. [PubMed]
  38. Di Spiezio Sardo A, De Angelis MC, Della Corte L, et al. Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer? Gynecol Oncol 2020;158:347-53. [Crossref] [PubMed]
  39. Della Corte L, Giampaolino P, Mercorio A, et al. Sentinel lymph node biopsy in endometrial cancer: state of the art. Transl Cancer Res 2020; [Crossref]
  40. Tozzi R, Ferrari F, Nieuwstad J, et al. Tozzi classification of diaphragmatic surgery in patients with stage IIIC-IV ovarian cancer based on surgical findings and complexity. J Gynecol Oncol 2020;31:e14. [Crossref] [PubMed]
  41. Tozzi R, Traill Z, Garruto Campanile R, et al. Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes. Gynecol Oncol 2016;143:35-9. [Crossref] [PubMed]
  42. Tozzi R, Soleymani Majd H, Campanile RG, et al. Feasibility of laparoscopic diaphragmatic peritonectomy during visceral-peritoneal debulking in patients with stage IIIC-IV ovarian cancer. J Gynecol Oncol 2020;31:e71. [Crossref] [PubMed]
  43. Soleymani Majd H, Ferrari F, Manek S, et al. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis. Gynecol Oncol 2016;140:430-5. [Crossref] [PubMed]
  44. Gadducci A, Tana R, Landoni F, et al. Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy. Eur J Gynaecol Oncol 2013;34:213-7. [PubMed]
  45. Ferrari F, Forte S, Ardighieri L, et al. Multivariate analysis of prognostic factors in primary squamous cell vulvar cancer: The role of perineural invasion in recurrence and survival. Eur J Surg Oncol 2019;45:2115-9. [Crossref] [PubMed]
  46. Grassi T, Dell’Orto F, Jaconi M, et al. Two ultrastaging protocols for the detection of lymph node metastases in early-stage cervical and endometrial cancers. Int J Gynecol Cancer 2020;30:1404-10. [Crossref] [PubMed]
  47. Lee J, Yu T, Tsai MH. Lymph Node Number Predicts the Efficacy of Adjuvant Chemoradiotherapy in Node-Positive Endometrial Cancer Patients. Diagnostics 2020;10:373. [Crossref] [PubMed]
  48. Phupong V, Intharasakda P. Twisted fallopian tube in pregnancy: A case report. BMC Pregnancy Childbirth 2001;1:5. [Crossref] [PubMed]
  49. Guo J, Qian H, Ma F, et al. The characteristics of isolated para-aortic lymph node metastases in endometrial cancer and their prognostic significance. Ther Adv Med Oncol 2020;12:1758835920933036. [Crossref] [PubMed]
Cite this article as: Ferrari F, Forte S, Arrigoni G, Ardighieri L, Coppola MC, Salinaro F, Barra F, Sartori E, Odicino F. Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer. Transl Cancer Res 2020;9(12):7697-7705. doi: 10.21037/tcr-20-2074

Download Citation